Abstract. The mouse progenitor T lymphocyte (proT) cell line FTF1 binds in vitro to thymus blood vessels, the thymic capsule, and liver from newborn mice. A mAb, EA1, raised against an embryonic mouse endothelial cell line, blocked adhesion . The antibody also interfered with proT cell adhesion to a thymus-derived mouse endothelial cell line; it had no effect on the adhesion of mature T lymphocytes and myeloid cells. The antigen recognized by EA1 is located on the vas-
49 The Rockefeller University Press, 0021-9525/91/09/1069/10 $2 .00 The Joumal of Cell Biology, Volume 114, Number 5, September 19911069-1078 1069 cular endothelium of various mouse tissues and absent on proT cells. EA1 antibody precipitates molecules with apparent molecular weights of 110,000, 140,000, 160,000, and 200,000. Immunoclearing and bindinginhibition studies with antibodies against known adhesion molecules suggest that the EA-1 antigen is a novel adhesion molecule involved in colonization of the embryonic thymus by T cell progenitors .
al ., 1990) . Most of these molecules can be induced to be expressed on certain endothelia by tissue inflammation in vivo or by cytokine treatment in vitro (Osbom, 1990) . Finally the integrins, consisting ofan ci and a ß subunit, are widely distributed on different tissues and participate in both, cell-cell and cell-substrate interaction . All these molecules seem to be involved in homing of various hemopoietic cell lineages to a variety of tissues. A more restricted tissue or organ-specific homing has been found in the lymphoid system (Streeter et al., 19ß8a; Springer, 1990b) . Thus, lymph nodes and Peyer's patches contain specialized blood vessels with a characteristic morphology, the high endothelial venules (HEV), to which mature lymphocytes bind. mAbs, directed against HEV antigens, block lymphocyte adhesion on HEV in the mucosa and others in peripherallymph nodes (Streeter et al., 19ß8b; Nakache et al., 1989) . Because such endothelial adhesion molecules are expressed in specific organs and because they seem to determine where circulating mature lymphocytes will exit the bloodstream, they are referred to as addressins .
Little is known about the interaction of lymphocyte progenitors with endothelium during development. Moreover, little is known about the existence ofadhesion molecules that participate in the homing of lymphocyte progenitors to particular tissues or organs (Tavassoli and Hardy, 1990) . We generated a mAb, EA-1, that reacts with a protein expressed on mouse endothelial cells. It inhibits the binding of proT cells to thymic endothelium, but it has no effect on adhesion of mature T lymphocytes or myeloid cells to tissues . Thus we provide evidence for restricted binding of T-cell progenitors to thymic endothelium, and we have identified on the surface of endothelial cells, a novel protein involved in that process .
The The development, characterization, and functional potential of the pro -T cell clone FTFI are described elsewhere (Pelkonen et al ., 1987 ; Palacios et al ., 1989) . They were grown in culture medium in the presence of Interleukin 2 as described (Palacios et al ., 1989) . For further binding studies we used the pre-B cell lymphoma 18-81 (Alt et al ., 1981) , early pre-B cell lymphoma 40E1 (Alt et al ., 1981) , the mature B cell line L10A62 (Kim et al ., 1979 ) and the carcinoma cell line KLN 205 (American Type Culture Collection, Rockville, MD) . Endothelial cells, eEnd .2 (derived from mouse embryo) and tEnd.l (derived from young mouse thymus), obtained from E . Wagner, Institute for Molecular Pathology (Vienna), are both endothelioma cell lines transformed by the polyoma middle T oncogene and cultured as described (Williams et al ., 1989) .
FITC (Sigma Chemical Co., St . Louis, MO) was prepared as a 25 .7 mM stock solution in DMSO (Fluka AG, Buchs, Switzerland) and processed as described . Briefly, 100 Kl stock solution was added to .End .l cells per well . Three independent experiments were taken with 10 wells per value. a 1 ml cell suspension containing between 0.5 and 4 x 107 cells in DME (Gibco BRL, Paisley, UK) and incubated at 4°C for 15 min in the dark . Labeled cells were then centrifuged through a layer of 5 ml 10% BSA for 15 min at 460 g at room temperature. Cells were washed with DME, and cell viability was assessed by the trypan blue dye exclusion test .
Cell Adhesion Assays
On Frozen Sections. In situ binding was performed on freshly prepared frozen sections from neonatal mouse tissue (Woodruff et al ., 1987 containing I % BSA for at least 10 min . Slides were dried around the Pappen marked area and the tissue section then loaded with 105 pro-T, lymphoma or carcinoma cells in 200 Al DPBS . Binding was allowed to occur for 40 min at 8°C on a mini-shaker (A . Kiihner AG, Basel, Switzerland) at 50 rpm . Slides were then placed vertically into DPBS containing 0.5% glutaraldehyde and 2 % formaldehyde, where nonbound cells were allowed to fall off. After 20 min of fixation at room temperature, pro T cells bound to the tissue section under study were counted using a light microscope (Axiophot ; Zeiss, Oberkochen, Germany) . On Cultured Cells. Endothelial cells were seeded into 96-well (no. 3596 ; Costar Data Packaging, Cambridge, MA) microtiter plates (3 x 104 cells/well) and cultured for 24 hr. After removing the medium, FITClabeled proT cells, peripheral T cells, or polymorphonuclear leukocytes were added (105 cells/2001c1/well) and incubated at 20°C for 2 h. Unbound cells were removed by washing three times with DPBS containing 1 % BSA ; the plates were "flicked" dry between washes . Fluorescence, corresponding to cells bound in DPBS, was measured by a Fluoroskan II reader flitertek, Elfab Oy, Finland) . The binding index is defined as the ratio of the number of cells bound to endothelium in the presence of blocking antibody to the number of cells bound in control medium .
Pblymorphonuclear Leukocytes, Peripheral TLymphocytes, and BloodPlatelets
For the isolation of leukocytes, we followed the protocol described by Lewinsohn et al . (1987) . Briefly, blood was centrifuged onto a Percoll cushion (83.6% Percoll, 1.6% H20, 14 .8% lOx HBSS, and 5 mM EDTA) . Cells from the interface were collected, stained with May-Grüpwald= Giemsa, and used for binding assays .
Peripheral T lymphocytes were obtained from mouse spleens by a negative sorting procedure . Briefly, to remove macrophages and B lymphocytes, spleen cells were incubated for 30 min with antibodies specific for macrophages (Mac-1) and B cells (B-220) followed by sheep anti-mouse IgG coated Dynabeads (40 beads/1 cell ; Dynal A .S., Oslo, Norway) . Bound cells were separated with the MACS magnet (Biotechnische Geräte, Gladbach, Germany) .
Blood platelets were prepared by differential centrifugation as described (Catalfamo and Dodds, 1989) .
Antibodies
Rabbit anti factor VIII serum was purchased from Behringwerke (Marburg, Germany) . Antibody H 154.163 (anti-LFA-1) was kindly provided by Dr. P Naquet (Centre d1nmunologie de Marseille Luminy, Marseille, France), YNl/1 .7 (and-ICAM-1) by Dr. F Tàkei (Karolinska Hospital, Stockholm, Sweden) . 142/5 (anti CD44) from Dr. I . S. Trowbridge (The Salk Institute, San Diego, CA), and polyclonal anti-EndoCAM by Dr. C. Buck (The Wistar Institute, Philadelphia) . Antibody Mel 14 was obtained from ATCC. Secondary antibodies were RITC-labeled goat anti-rabbit IgG (Cappel Laboratories, Cochranville, PA), FITC-labeled goat anti-rat IgG (Jackson Immuno Research Laboratories Inc., Avondale, PA), FITC-labeled anti-rat IgG28, and Biotin anti-rat IgG2b (both from The Binding Site LTD, Birmingham, UK) . Biotin-labeled streptavidin was from Amersham International (Amersham, UK) .
The rat mAb EA 1, a IgG2 was prepared according to an immunization and cell fusion protocol described by Dr. M . Kosco (manuscript in preparation) . Confluent endothelial cells (eEnd .2) from a 150 cm 2 culture flask were irradiated with 10,000 rod and harvested with cell scrapers (Costar Data Packaging) . These cells were then washed with DPBS, mixed 1 :1 with complete Freund's adjuvant for a final volume of 30011, and injected subcutaneously into the dorsal surface of the hind foot of a 2-mo-old PVG rat . Injections with cells in DPBS only were repeated after 7 and 14 d. At day 17, the draining popliteal lymph node was dissected from the rat . The tissue was enzymatically digested using the following enzyme stock solutions : 150 mg/ml protease type IX (P-6141 ; Sigma Chemical Co .) ; 8 mg/ml collagenase CLS 4 (Worthington Biochemical Corp., Freehold, NJ) ; 10 mg/ml Imhof et al . EA-1 : thymus-homing Adhesion molecule 1073
DNAse I (D-0876; Sigma Chemical Co.) . The enzyme solutions were mixed to a final volume of 2 ml (0.5 ml Collagenase, 0.1 ml Protease, 0.1 ml DNAse, 1 .3 ml IMDM [Iscoves modified MEM ; Gibco BRL]) . A lymph node was opened by two slight crosscuts using a 25-gauge needle. Stroma were then digested at 37°C for two 30-min periods each with 1 ml enzyme cocktail . The cells were then carefully released into IMDM with Pasteur pipettes, washed in 50 ml IMDM, and counted . One part lymph node cells was then mixed with five parts mouse Sp2/0 myeloma cells, centrifuged, and fused with PEG 4,000 (E . Merck, Darmstadt, Germany) as described in Harlow and Lane (1988) . The cells were then plated (100 Al) into conditioned medium in microtiter plates (96 wells ; Costar Data Packaging) at a density of 5 x 104 cells/well in IMDM selection medium containing HAT (Gibco BRL), 10% FCS (Boehringer Mannheim GmbH, Mannheim, Germany), 50 AM 0-mercaptoethanol, penicillin/streptomycin, and glutamine. Conditioned medium was produced by culturing 104 PVG rat thymocytes (10011/well) in selection medium for three days before fusion . The IgG was purified from hybridoma supernatant on protein G affinity columns (Pharmacia Fine Chemicals, Uppsala, Sweden) .
Immuno,fluorescence
Frozen sections were fixed with acetone and labeled with supernatant of the EA-I hybridoma raised against eEnd . The cells in suspension were stained by unlabeled EA1 followed by the same FITC-conjugated goat anti-rat IgG described above.
Immunoprecipitation
To determine the molecular weight of the protein recognized by EA-1, confluent endothelial cells grown in a 150-cm2 , culture flask were surface iodinated by the lactoperoxidase/glucoseoxidase method described elsewhere (Marchalonis, 1969) . Briefly, cells were washed twice with DPBS and incubated with 1 .5 mCi 125 Iodine, 2 ml DPBS containing 1 U/ml lactoperoxidase, 2 U/ml Glucoseoxidase, and 0.2 % 0-i>-glucose. After 30-min incubation at room temperature, the cells were washed eight times with complete medium. Radioactive cells in DPBS containing 2 mM PMSF (Sigma Chemical Co .) and 1 TIU/ml Aprotinin (Sigma Chemical Co.) were harvested from the flask with a cell scraper (Costar Data Packaging) . The cells were suspended in lysis buffer (2 % NP-40 [Fluka AG], 150 mM NaCl, 50 mM Tris, pH 8, 2 mM PMSF, and 1 TIU/ml Aprotinin) and centrifuged for 10 min at 10,000 g . The supernatant was cleared twice with 100 141 Sansorbin (Calbiochem-Behring Corp., San Diego, CA) and a rabbit anti-rat serum (Jackson Laboratory, Bar Harbor, ME) for 30 min each . Hybridoma supernatant and a rabbit anti-rat serum (1 :20) was added to an aliquot of the cleared lysate and precipitation was performed using 3014 Pansorbin (Calbiochem-Behring Corp .) . Pellets were washed three times with lysis buffer, boiled in SDS-dissociation buffer, and run on SDS-PAGE, 5-15% acrylamide.
Results

PTFI pro-TCells Bind to Thymic TYssue
The FTF1 cell line has cellular, molecular, and functional properties of pro T cells, the progenitors that are the earliest stage of T cell development (Pelkonen et al., 1987; Palacios et al., 1989) . FTFl cells express the proT cell specific sur- The Journal of Cell Biology, Volume 114, 1991 fore, we thought that the behavior of FTFI proT cells in functional thymus homing assays in vitro would be a measure of interactions between proT cells and thymic tissue in vivo (Stamper and Woodruff, 1976) . We find that FTFI cells bind to frozen sections of thymuses from newborn mice. They are concentrated on the thymic capillaries and especially to the larger blood vessels of the thymic cortico-medullary junction (Fig . 1 A) . They also adhere to areas in the outer cortex and in the capsule of the isolated thymus, but less frequently. The FTF1 pro-T cells also bind to frozen sections of liver from newborn mouse, but they did not adhere to kidney, lung, or heart tissues . Twice as many FTFI cells adhered to the thymus than to the liver (Fig . 1 B and Table I A) . Thus, in contrast to other cell lines tested, as would be expected of a proT cell, FTF1 shows a clear preference for adhering to hemopoietic organs .
mAb EA1 Inhibits proT Cell Adhesion to Thymic Endothelium
In an attempt to identify adhesion molecules involved in homing to the thymus, we prepared rat mAbs against the endothelial cell line eEnd .2 (derived from mouse embryonic tissue ; Williams et al ., 1989) and tested them in the frozen section binding assay. The antibody EA1 totally blocked the binding of FTFI, partially a carcinoma but not the other hemopoietic cell lines to neonatal thymus ( Fig . 2 and Table I B) . The limited binding of FTFI proT cells to neonatal liver was only partially blocked . Thus the antigen recognized by EA1 antibody seems to be more important for the adhesion of proT cells to thymic tissue than it is for their adhesion to liver.
To study binding to endothelia in vitro, we have developed an automated assay which involved culturing FTFI pro -T cells labeled with fluorescenn isothiocyanate on a layer of the thymus derived endothelial cell line tEnd .l (Williams et al ., 1989 ; Imhof et al ., 1990) . A microtiter reader equipped with a fluorimeter was used to count fluorescent cells adhering to this monolayer. The antibody, EA-1, inhibited binding of FTF1 cells to tEnd .l endothelia in control medium by 60% (Fig . 3) . EA1 did not affect the binding of mature peripheral T cells to the thymic endothelial cell line (Fig . 3) , nor did it affect the adhesion of polymorphonuclear leukocytes (data not shown) .
Using FACS (Becton Dickinson and Co .) analysis we established that EA1 recognized a cell surface antigen on endothelial cell lines of either embryonic (eEnd .2) or thymic (tEnd .l) origin . FTFI proT cells did not bind EA-1 (Fig . 4) . These findings suggest that the EA-1 antigen on endothelia recognizes an as yet undefined molecule on proT cells.
Tissue Distribution of the Antigen Recognized by EA1
Using an analysis by immunofluorescence staining and microscopy of frozen sections from newborn mouse tissue we showed that the EA1 antibody stains blood vessels in the thymus . The endothelial nature ofthe cells positive for EA1 was demonstrated by double labeling assays with EA-1 and antifactor VIII antibodies as an endothelial marker (Fig. 5) . The labeling pattern of EA-1 on the luminal side of endothelial cells was compared with that in regions of cell-cell contact . We found that EA-1 reacts with an antigen present on all thymic capillaries . However, the EA-1 antibody also bound to vascular endothelia in newborn liver, spleen, lung, kidney, and brain ( Fig. 5 ; and data not shown) . In adult tissues, the antigen recognized by EA-1 was detected on endothelia of many tissues (as shown in Fig. 5 for spleen) , on a subpopulation of immature hemopoietic cells from the bone marrow ( Fig. 6 ) and, on freshly isolated blood platelets ( 
Relationship ofEA1 Antigen to Other Cell Adhesion Molecules
It is known that several adhesion molecules known to be expressed on endothelial cells can be upregulated by inflammatory reactions mediated by endotoxins or cytokines . IL-1 failed to induce a higher expression of the EA-1 antigen on the endothelial cell line eEnd.2, but INF-y had a slight effect on a negative subpopulation (Fig. 7) . Another adhesion molecule, CD44, showed no significant change. By contrast LFA-1, ICAM-1 and gp9() Me114 were upregulated upon cytokine treatment . Induction of LFA-1 and gp90MA14 expression on eEnd.2 cells by IL-1 is a novel and interesting finding . It may be because of the fact that this particular cell line is of embryonic origin.
In analogy to the induction of adhesion molecules, inflammatory reactions increase the binding capacity of endothelium for myeloid cells or mature lymphocytes (Osborn, 1990) . We found that treatment of eEnd.2 endothelium with IL-1 reduced pro-T cell binding (Fig. 8A) . By contrast, polymorphonuclear leukocytes bound slightly better to endothelia treated with IL-1 or IFN-y (Fig. 8 B) .
Antibodies directed against the known adhesion molecules, LFA-1, CD44, and gp90
M°114 did not interfere with proT cell adhesion to tEnd.l endothelial cells (Fig. 9 A) . Interestingly, antibodies against the integrin LFA-1 slightly increased the inhibitory effect of EA-1 antibodies (Fig. 9 B) .
Immunoprecipitation of the Antigen Recognized by EA1
After surface iodination, endothelial cell (eEnd.2) proteins were solubilized and immunoprecipitated with EA1. SDS-PAGE, under reducing conditions, detected bands at a molecular weight of 110,000, 140,000, 160,000, and 200,000 (Fig. 10) . Nonreducing conditions did not significantly change the pattern. However, depending on experimental conditions the intensity ofthe individual bands varied, probably because of limited digestion. The molecular weight of one band (140,000) is similar to that of PECAM/endo-CAM/CD31 which is also expressed on endothelia and platelets. But using immunoclearing with a polyclonal anti-CD-31 antiserum, we could clearly show that the two molecules are different (Fig. 10) . . Adhesionmolecules involved in inflammation do not interfere with pro-T cell adhesion. Binding ofFTFI cells on tEnd.l endothelia was performed as described in Fig. 3 . Antibodies against LFA-1, CD44, and gpgoMei-14, and the antibody EA-1, were added as hybridoma supematants in the FTFI binding assay. Synergistic effects of the various adhesionmolecules onFTFI binding were studied by mixing the above antibodies with EA1 in the adhesion assay. Only anti-LFA1 showed a minor effect. The number ofboundFTFI control cells was the same as in Fig. 3 . Here we have shown that proT lymphocytes bind to thymus and liver from newborn mice as well as to an endothelial cell line derived from thymus . This property of T-cell progenitors appears restricted to vessels in hemopoietic tissue ; that is, they do not adhere to endothelia in other organs such as kidney, lung, or heart . The EA-1 antibody reacts with molecules of apparent molecular weights of 110,000, 140,000, 160,000, and 200,000, which are components of the plasma membrane of endothelial cells .
Although it recognizes an antigen expressed on vascular endothelium from several tissues, EA1 effectively blocks the binding of proT cells to thymus-derived endothelium, but it does not affect the adhesion of mature T lymphocytes or myeloid cells to any tissue . This result strongly suggests that the molecules recognized by the EA-1 antibody on endothelial cells selectively participate in the adhesion of proT cells to thymic endothelium . EA-1, located on other tissues may either not be functional or it could be involved in homotypic
The Journal of Cell Biology, Volume 114, 1991 endothelial cell-cell contact . The specificity of EA-1 antigen for proT cells in the thymus might result from interaction of the endothelium with the thymus in a way that alters its binding affinity. Such a process is also thought to be involved in LFA1-mediated adhesion and deadhesion of lymphocytes Figdor et al ., 1990) . Specificity might also result from posttranslational modifications of the antigen, as had been shown for the receptor molecule of ELAM-1 or PADGEM/GMP-140, lacto-N-fucopentaose III (Walz et al., 1990; Larsen et al., 1990; Lowe et al., 1990; Phillips et al ., 1990) . Moreover, different adhesion molecules may act together and tissue specificity is probably created by the proportional number of these molecules to each other (Hamann et al ., 1988) .
In addition to proT cells, peripheral mature T cells and polymorphonuclear leukocytes adhere to the endothelial cell lines tested here . But EA1 antibody specifically blocked the adhesion of FTF1 proT cells without affecting that of other hemopoietic cell lineages. Also, IL-1, a cytokine involved in inflammatory reactions, stimulated the binding of myeloid cells but had a negative effect on proT cell binding . Thus, the binding of these various hemopoietic cells seems to depend on interaction with a different set of adhesion molecules . Moreover, these results suggest that the homing of proT cells to the thymus uses molecular mechanisms different from those described for inflammation mediated cell adhesion to endothelia . The in vitro assay described here ought to prove valuable in studying thymic specific homing mechanisms involved in embryonic pattern formation .
The EA1 Antigen Is A Novel Adhesion Protein
The question arises whether the EA-1 antigen is a novel molecule or whether proT cell binding to thymic endothelium is a function of a previously described adhesion molecule . PADGEM/GMF-140, a protein-mediating cell adhesion of hemopoietic cells to endothelia, has a similar tissue distribution and the same molecular weight as the EA-1 antigen (Johnston et al ., 1989 ; Parmentier et al ., 1990) . However several experiments reveal major differences between the two molecules . EA-1 is mainly expressed on the cell surface, whereas GMP-140 colocalizes with factor VIII, in WeibelPalade bodies in endothelial cells (Bonfanti et al., 1989) . Only inflammatory activation of the cells brings GMP-140 to the cell surface (Osborn, 1990) . EA-1 is constitutively expressed on endothelial cell surfaces and stimulation of these cells by IL-1 does not increase the expression of EA-1. PECAM-1/EndoCAM, another adhesion molecule found on endothelium is found on the apical plasma-membrane and in cell-cell junctions of endothelial cells . Its published molecular weight is 130 kd (Newman et al., 1990) . Identity with EA-1 could be excluded by immunoclearing, which was possible because of bovine/mouse crossreactivity of a polyclonal anti-EndoCAM antibody . The other adhesion molecules ELAM-1, PgPLl/CD44, I-CAM, gpgoME . ", 01, and ß4 integrins differed from EA-1 in molecular weight, tissue distribution pattern, and their regulation of cell surface expression (Pont et al .; Simmons et al 1988; Picker et al., 1989; Zhou et al., 1989 ; Siegelman et al ., 1989; Hogervost et al ., 1990; Stoolman, 1990) . Therefore, we conclude that the EA-1 antigen has not been previously described. Our data suggest that it selectively plays a role in the adhesion of T lymphocyte progenitor cells to endothelium . Interestingly, the EA-1 antigen may also be involved in carcinoma cell adhesion to endothelium . Adhesion molecules used by cells ofthe immune system have already been found to play a role in cancer metastasis and they may open possibilities of applications in therapy (Rice et al., 1989; Giinthert et al., 1991) . We are currently attempting to isolate cDNA encoding the molecule recognized by EA-1 antibody to further define the nature, function, and relatedness of this protein with other adhesion molecules .
